Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 151.19% | -3.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 151.19% | -3.32% |
| Cost of Revenue | -27.42% | -25.85% | -14.28% | -22.97% | 9.79% |
| Gross Profit | 16.28% | 18.01% | 4.46% | 26.34% | -12.12% |
| SG&A Expenses | -27.16% | -24.39% | -15.38% | -19.66% | -3.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.36% | -25.57% | -14.50% | -22.28% | 6.53% |
| Operating Income | 18.90% | 19.36% | 6.90% | 24.98% | -7.81% |
| Income Before Tax | 84.07% | 35.66% | 84.41% | -1,248.64% | -32.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.07% | 35.66% | 84.41% | -1,248.64% | -32.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.07% | 35.66% | 84.41% | -1,248.64% | -32.69% |
| EBIT | 18.90% | 19.36% | 6.90% | 24.98% | -7.81% |
| EBITDA | 18.35% | 18.79% | 6.10% | 24.48% | -7.66% |
| EPS Basic | 88.66% | 54.27% | 88.87% | -1,174.50% | 55.36% |
| Normalized Basic EPS | 87.96% | 54.26% | 88.86% | -1,171.56% | 57.98% |
| EPS Diluted | 88.66% | 54.27% | 88.87% | -1,174.50% | 55.36% |
| Normalized Diluted EPS | 87.96% | 54.26% | 88.86% | -1,171.56% | 57.98% |
| Average Basic Shares Outstanding | 40.53% | 40.68% | 40.00% | 5.81% | 197.23% |
| Average Diluted Shares Outstanding | 40.53% | 40.68% | 40.00% | 5.81% | 197.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |